

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA pegunigalsidase alfa for treating Fabry disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

During scoping, the clinical experts discussed the possibility of defining males with classic Fabry disease as a specific subgroup because treatments may be more cost effective in this group. However, concerns were raised about the potential for inequity of access to treatment based on sex. So, it was agreed that males with classic Fabry should not be a specific subgroup.
--

The committee's decision to recommend pegunigalsidase alfa as an option for treating Fabry disease applies to all people with Fabry disease regardless of sex.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

None raised.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

None identified.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
No further equality issues were raised in the submissions. The committee's decision to recommend pegunigalsidase alfa as an option for treating Fabry disease applies to all people with Fabry disease regardless of sex.

Approved by Associate Director (name): ...Richard Diaz.....

Date: 21 July 2023